Population Genomics Market (2026-2036)

The growth of this market is mainly driven by the launch and expansion of national genomics programs and population-scale biobanks, the integration of genomic data with electronic health records to support precision medicine, the growing use of population genomic data in drug target discovery, and the declining cost of whole-genome and exome sequencing. In addition, the introduction of newborn and preventive genomic screening programs, the emphasis on genetic diversity in research cohorts, the expansion of long-read and multiomic sequencing, and the use of cloud-based trusted research environments and artificial intelligence (AI) to analyze very large datasets are further supporting the growth of this market.

The Population Genomics Market, also referred to as the national genomics programs market, population-scale sequencing market, or biobank genomics market, comprises the instruments, consumables and reagents, services, and software and data platforms used to sequence, genotype, store, and analyze the genomes of large populations. The market includes short-read and long-read sequencers, genotyping arrays, sequencing and library preparation reagents, sequencing and genotyping services, data analysis and interpretation services, bioinformatics software, and cloud-based data platforms and trusted research environments used by national genomics programs, biobanks, health systems, research consortia, and pharmaceutical companies. Population genomics programs combine genetic data with health records, lifestyle information, and increasingly proteomic, epigenomic, and other multiomic data to understand the genetic basis of disease, improve diagnosis and prevention, and discover new drug targets. The market ecosystem extends from technology providers and sequencing service laboratories to data platform providers, governments and public health agencies, health systems, research institutions, and pharmaceutical companies.

The market is experiencing strong growth as governments and health systems invest in genomics as a foundation for precision medicine. Large population datasets allow researchers to identify genetic variants associated with disease, understand how genetic risk differs across populations, and develop tools such as polygenic risk scores and pharmacogenomic guidance. At the same time, the declining cost of sequencing has made it feasible to sequence whole genomes or exomes for hundreds of thousands to millions of people, transforming population genomics from a research activity into a component of national health strategies.

National programs in North America and Europe are among the largest in the world. In June 2026, the All of Us Research Program of the U.S. National Institutes of Health (NIH) expanded its dataset to more than 747,000 participants, including 535,000 whole-genome sequences, nearly 482,000 linked electronic health records, and more than 1.3 billion genetic variants, with more than 86% of participants from communities historically underrepresented in health research. The U.S. Department of Veterans Affairs Million Veteran Program has enrolled more than one million veterans. In the U.K., UK Biobank released whole-genome sequence data for about 500,000 participants, and its Pharma Proteomics Project, a collaboration with 14 biopharmaceutical companies, is measuring more than 5,400 proteins in up to 600,000 samples. Our Future Health in the U.K. has recruited more than 2 million consented participants and released genotype data for 755,000 participants, with imputed genotype data first released in December 2025 and genetic ancestry data in May 2026, while Eurofins Genomics was selected to genotype up to 5 million participants. Genomics England is running the Generation Study, which aims to sequence the genomes of 100,000 newborns to evaluate whether genome sequencing can identify more than 200 rare genetic conditions, and expects the National Genomic Research Library to hold more than 500,000 whole genomes by 2030, supporting the ambition in the NHS 10 Year Health Plan to offer genomic sequencing at birth.

Health systems and pharmaceutical companies are also investing directly in population sequencing. In January 2025, Truveta and more than 30 U.S. health systems launched the Truveta Genome Project, with the goal of sequencing the exomes of the first 10 million volunteers, with sequencing performed by the Regeneron Genetics Center, which has sequenced about three million exomes to date, and strategic investments from Regeneron, Illumina, and 17 health systems. These initiatives link genetic data with real-world clinical data from health systems, creating resources for drug discovery and clinical research, and reflect the growing value that pharmaceutical companies place on large genetic datasets. The sale of the assets of 23andMe to TTAM Research Institute for USD 305 million in 2025, after a competing proposal from Regeneron Pharmaceuticals, further illustrates the strategic value of large genetic databases.

Asia-Pacific and the Middle East are emerging as major centers of population genomics. The Emirati Genome Programme had sequenced more than 600,000 genomes by late 2024, including 100,000 using long-read sequencing combined with epigenetic data, with the M42 Omics Centre of Excellence operating one of the largest genomics facilities in the world, toward a target of one million samples. In January 2025, India released the Indian Genomic Dataset of 10,000 whole genomes through the GenomeIndia project, accessible through the Indian Biological Data Centre, and the Ministry of Science and Technology has set a goal of sequencing about 10 million genomes reflecting the diversity of the Indian population. In Singapore, the PRECISE-SG100K population health study is generating genomic and proteomic data, supported by collaborations with Thermo Fisher Scientific and Seer. These programs reflect a growing emphasis on generating genetic data for populations that are underrepresented in existing datasets.

Technology innovation is expanding the scope of population genomics. Long-read sequencing is being used to capture structural variants and methylation, as in the 100,000 long-read genomes of the Emirati Genome Programme, while PacBio reported the start of sequencing for a population-scale program for Basecamp Research in 2026. Ultra-low-cost sequencing platforms, such as the UG 100 platform of Ultima Genomics, which was selected for the UK Biobank proteome study, and new chemistries that combine genetic and methylation information, such as the Illumina 5-Base Solution, are increasing the information obtained per sample and reducing costs.

At the same time, the market faces challenges related to funding, data privacy, and the complexity of managing very large datasets. NIH funding for the All of Us Research Program was about USD 158 million in fiscal year 2025, roughly 71% lower than in fiscal year 2023, illustrating the dependence of many programs on public funding. As a result, providers that can offer low-cost, high-throughput sequencing, secure data platforms, and analysis that delivers clinical and research value are expected to capture the largest share of growth over the forecast period.